Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
MOUNTAIN VIEW, Calif. and SEATTLE, Oct. 6 /PRNewswire/ -- Complete Genomics Inc., a newly launched, third-generation human genome sequencing company, and the Institute for Systems Biology (ISB) today announced their partnership to conduct populationwide human genome studies.
In phase one of the project, Complete Genomics will use its proprietary DNA sequencing technology to sequence five genomes from samples provided by ISB. Then, once proof-of-concept has been demonstrated, ISB and Complete Genomics plan to expand this collaboration to sequence the genomes of 100 individuals in 2009 and 2,000 individuals in 2010.
"Using Complete Genomics' human genome sequencing services to gather populationwide human genetic data will allow us to gain a more complete understanding of the genetic components and molecular processes of diseases in order to better manage, treat and prevent human disease and better understand human health," said Dr. Leroy Hood, president of ISB and member of Complete Genomics' Scientific Advisory Board.
"This collaboration demonstrates the value of our sequencing service business model and underscores our vision of using our large-scale, low-cost DNA sequencing technology to elucidate disease pathways," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "We are pleased to be partnering with such a renowned organization as the Institute for Systems Biology on a project that will provide the data that researchers need to develop better drugs, therapeutics and diagnostics."
About Complete Genomics
Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA. Complete Genomics plans to combine its proprietary third-generation DNA sequencing technology and its high-performance computing capabilities to create a human genome sequencing service that will deliver low-cost, high-quality data on an unprecedented scale. The company is currently building the world's largest human genome sequencing center. This development will allow pharmaceutical and biotechnology customers, for the first time, to conduct large-scale human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information about the company, please visit http://www.completegenomics.com.
About the Institute for Systems Biology
Founded in 2000, the Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. ISB seeks to use systems methods to unravel the complexity of human biology and identify strategies for predicting and preventing significant diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, focusing on entire, complex biological systems rather than one gene or protein at a time. For more information about ISB, visit http://www.systemsbiology.org.
CONTACT: Jennifer Turcotte, Vice President of Marketing of Complete
Genomics Inc., +1-650-943-2846, jturcotte@completegenomics.com; or Lisa
Osborne, Account Director of Waggener Edstrom Worldwide Healthcare,
+1-202-261-7806, lisao@waggeneredstrom.com, for Complete Genomics Inc.; or
Todd Langton, Associate Director of Communications and Public Relations of
Institute for Systems Biology, +1-206-732-1333, tlangton@systemsbiology.org
Web site: http://www.completegenomics.com/
http://www.systemsbiology.org/